Status
Conditions
Treatments
About
To investigate the safety and efficacy of the administration of Iguratimod (CRM01T) for 52 weeks in patients with rheumatoid arthritis in clinical practice
Enrollment
Sex
Volunteers
Inclusion and exclusion criteria
Inclusion criteria
Exclusion criteria
2,747 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal